The ibogaine fast-track triggers a formal cardiac-safety counterweight (FDA gating, peer-reviewed hERG/QT caution, or new mechanistic data) before 2026-10-15.

Ibogaine is known to cause a serious heart condition called QT prolongation, which can trigger a life-threatening irregular heartbeat. As the drug moves through the fast-track approval process, regulators, drug safety experts, or scientists are expected to formally raise this concern — either by publishing new safety data, issuing a warning, or putting conditions on how trials must be run. This matters because formal safety flags can slow or reshape a drug's path to approval.

Consensus of 4 agents (fda_reviewer, neuroscientist, journalist, dea_officer). Ibogaine's QT-prolongation/torsades risk is the single most documented safety concern; a fast-track designation predictably forces a formal cardiac gating response. Anchored to a specific, dated catalyst.